The Vasodilatory Effects of Levosimendan on the Human Internal Mammary Artery

BACKGROUND: Levosimendan, an inotropic drug that enhances myocardial contractility through myofilment calcium sensitazion, induces peripheral vasodilation via opening ATP-dependent K+ channels. It is unknown whether this drug can be used for the treatment of perioperative vasospasm of arterial conduits used for coronary artery bypass grafting. METHODS: We investigated the effects of levosimendan on human internal mammary artery (IMA) specimens taken from patients undergoing coronary artery bypass surgery. The rings were carefully prepared and placed between two wire hooks in organ bath chambers and then constricted submaximally with norepinephrine and thromboxane A2 analog (U46619). Nitroglycerin, milrinone, and levosimendan were separately added in a cumulative fashion and concentration response curves for relaxation were constructed. In parallel experiments, the response to levosimendan was evaluated on rings with and without functional endothelium. Levosimendan prevention of norepinephrine-induced contraction was also estimated. RESULTS: Nitroglycerin, milrinone, and levosimendan completely reversed the contraction of the IMA segments induced by U46619 and norepinephrine. Levosimendan produced a potent, concentration-dependent preventive effect on the norepinephrine-induced contraction of IMA. The responses to levosimendan were similar in preparations with or without endothelium.

[1]  F. Szlam,et al.  In vitro effects of antihypertensive drugs on thromboxane agonist (U46619)-induced vasoconstriction in human internal mammary artery. , 2004, British journal of anaesthesia.

[2]  Christopher M O'Connor,et al.  Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.

[3]  S. Hashimoto,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Glyceryl Trinitrate and its Metabolites , 2003, Clinical pharmacokinetics.

[4]  L. Ignarro,et al.  Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. , 2002, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[5]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[6]  E. Bayer,et al.  An Analysis of Responses to Levosimendan in the Pulmonary Vascular Bed of the Cat , 2002, Anesthesia and analgesia.

[7]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[8]  P. Pentikäinen,et al.  Pharmacodynamics and Safety of a New Calcium Sensitizer, Levosimendan, and Its Metabolites during an Extended Infusion in Patients with Severe Heart Failure , 2002, Journal of clinical pharmacology.

[9]  J. Papp,et al.  Comparison of the Vasorelaxing Effect of Cromakalim and the New Inodilator, Levosimendan, in Human Isolated Portal Vein , 2000, The Journal of pharmacy and pharmacology.

[10]  P. Pagel,et al.  Levosimendan, a New Positive Inotropic Drug, Decreases Myocardial Infarct Size via Activation of KATP Channels , 2000, Anesthesia and analgesia.

[11]  A. Nicolosi,et al.  Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. , 1999, Journal of cardiovascular pharmacology.

[12]  A. Dominiczak,et al.  Pharmacological characterisation of endothelium-dependent relaxation in human radial artery: comparison with internal thoracic artery. , 1999, Cardiovascular research.

[13]  F. Rosenfeldt,et al.  Pharmacology of coronary artery bypass grafts. , 1999, The Annals of thoracic surgery.

[14]  F. Szlam,et al.  A Comparative Evaluation of the Effects of Multiple Vasodilators on Human Internal Mammary Artery , 1998, Anesthesiology.

[15]  M. Nieminen,et al.  Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. , 1998, European heart journal.

[16]  L. Doolan,et al.  Direct vasodilator effect of milrinone, an inotropic drug, on arterial coronary bypass grafts. FANZCA . , 1997, The Journal of thoracic and cardiovascular surgery.

[17]  J. Papp,et al.  Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. , 1995, Circulation research.

[18]  A. Starr,et al.  Overview of the nature of vasoconstriction in arterial grafts for coronary operations. , 1995, The Annals of thoracic surgery.

[19]  M. Kikura,et al.  Pharmacokinetics of Intravenous Milrinone in Patients Undergoing Cardiac Surgery , 1994, Anesthesiology.

[20]  A. Carpentier,et al.  Vasoreactivity of the Radial Artery Comparison With the Internal Mammary and Gastroepiploic Arteries With Implications for Coronary Artery Surgery , 1993, Circulation.

[21]  M. Hsieh,et al.  Thromboxane A2: an endothelium-derived vasoconstrictor in human internal mammary arteries. , 1993, The Annals of thoracic surgery.

[22]  F. Rosenfeldt,et al.  Reactivity of human isolated internal mammary artery to constrictor and dilator agents. Implications for treatment of internal mammary artery spasm. , 1989, Circulation.

[23]  G E Reed,et al.  Early postoperative spasm in left internal mammary artery bypass grafts. , 1987, The Annals of thoracic surgery.

[24]  W. C. Sheldon,et al.  Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. , 1986, The New England journal of medicine.